Tandem Diabetes Care is a medical device company that specializes in the development and manufacturing of innovative products for people with diabetes
The company focuses on creating advanced insulin delivery systems, including insulin pumps and related software solutions, designed to improve the management of diabetes for individuals who rely on insulin therapy. By leveraging cutting-edge technology, Tandem aims to enhance the user experience, offering features such as automated insulin delivery and seamless data integration, ultimately helping patients achieve better health outcomes and greater convenience in their daily lives.
Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
Diabetes technology company Tandem Diabetes Care (NASDAQTNDM) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 35% year on year to $282.6 million. The company expects next quarter’s revenue to be around $221.5 million, coming in 1.3% above analysts’ estimates. Its GAAP profit of $0.01 per share was significantly above analysts’ consensus estimates.
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges.
RBC Capital Markets initiates coverage on Tandem Diabetes Care (TNDM) with an Outperform rating and $65 price target, citing growth opportunities in the U.S. Type 1 and Type 2 diabetes markets, product innovations, and improved margins driven by the Mobi launch.
